Literature DB >> 6477833

Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS.

G Tricot, C De Wolf-Peeters, R Vlietinck, R L Verwilghen.   

Abstract

A study has been performed of 40 bone marrow trephine biopsies from patients with myelodysplastic syndromes (MDS). Histology, more specifically the abnormal localization of immature precursors (ALIP), cytology and karyotype analysis were correlated with survival time and the prognostic value of these factors was determined. The presence or absence of ALIP proved to be highly significant in predicting the duration of survival (P = 0.007): the presence of ALIP predisposes patients to early death with high probability of developing acute myeloid leukaemia (AML), whereas the absence of ALIP carries a better prognosis with more long-term survivors and low probability of transformation to AML. The presence or absence of ALIP was not correlated with increased mortality from infection and/or bleeding. In contrast with ALIP, the main histological parameter, we were not able to obtain statistically significant prognostic information for cytology (FAB classification) or karyotype analysis (normal or abnormal chromosomes). We conclude that bone marrow biopsy provides useful information for the prognosis of MDS and that the presence of ALIP has greater predictive value than the more commonly used parameters deduced from cytology and karyotype.

Entities:  

Mesh:

Year:  1984        PMID: 6477833     DOI: 10.1111/j.1365-2141.1984.tb06079.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

Review 1.  Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia.

Authors:  D A Winfield; S V Polacarz
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

2.  Immunohistochemical identification of erythroid precursors in paraffin embedded bone marrow sections: spectrin is a superior marker to glycophorin.

Authors:  Y Sadahira; A Kanzaki; H Wada; Y Yawata
Journal:  J Clin Pathol       Date:  1999-12       Impact factor: 3.411

3.  Angiogenesis and survival in patients with myelodysplastic syndrome.

Authors:  Aleksandar Savic; Vesna Cemerikic-Martinovic; Sinisa Dovat; Nebojsa Rajic; Ivana Urosevic; Borivoj Sekulic; Vanja Kvrgic; Stevan Popovic
Journal:  Pathol Oncol Res       Date:  2012-01-24       Impact factor: 3.201

4.  Long-term survivors in myelodysplastic syndromes: clinical and biological characteristics.

Authors:  Dragomir Marisavljević; Zoran Rolović; Darinka Bosković; Milica Colović
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

5.  Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts.

Authors:  G Kerndrup; B Pedersen; J Ellegaard; P Hokland
Journal:  Blut       Date:  1986-01

Review 6.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

7.  Myelodysplastic syndrome: An update on diagnosis and therapy.

Authors:  Ahrin Koppel; Gary Schiller
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

8.  Abnormal localization of immature precursors (ALIP) detection for early prediction of acute myelocytic leukemia (AML) relapse.

Authors:  Hai-Qing Huang; Xiang-Zhong Fang; Jun Shi; Jie Hu
Journal:  Med Biol Eng Comput       Date:  2013-12-21       Impact factor: 2.602

9.  Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.

Authors:  G Lambertenghi-Deliliers; C Annaloro; A Oriani; D Soligo; E Pozzoli; E E Polli
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

Review 10.  Myelodysplastic syndrome: an update on diagnosis and therapy.

Authors:  Ahrin Koppel; Gary Schiller
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.